Compare PODD & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PODD | BAX |
|---|---|---|
| Founded | 2000 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.0B |
| IPO Year | 2007 | 1994 |
| Metric | PODD | BAX |
|---|---|---|
| Price | $144.22 | $19.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 9 |
| Target Price | ★ $341.48 | $21.00 |
| AVG Volume (30 Days) | 1.3M | ★ 6.5M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | $2,708,100,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $24.55 | $1.96 |
| Revenue Next Year | $19.18 | $2.22 |
| P/E Ratio | $111.97 | ★ N/A |
| Revenue Growth | ★ 30.73 | 5.72 |
| 52 Week Low | $140.63 | $15.73 |
| 52 Week High | $354.88 | $31.76 |
| Indicator | PODD | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 55.42 |
| Support Level | $143.11 | $19.29 |
| Resistance Level | $161.35 | $19.90 |
| Average True Range (ATR) | 6.16 | 0.68 |
| MACD | 0.90 | -0.01 |
| Stochastic Oscillator | 14.97 | 54.15 |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.